학술논문
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
Document Type
Article
Author
Source
Journal of Cellular & Molecular Medicine; May2024, Vol. 28 Issue 9, p1-17, 17p
Subject
Language
ISSN
15821838
Abstract
Copyright of Journal of Cellular & Molecular Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)